Oncolytics Selling And Marketing Expenses from 2010 to 2024

ONCY Stock  USD 0.93  0.02  2.11%   
Oncolytics Biotech Selling And Marketing Expenses yearly trend continues to be fairly stable with very little volatility. Selling And Marketing Expenses is likely to outpace its year average in 2024. During the period from 2010 to 2024, Oncolytics Biotech Selling And Marketing Expenses regression line of annual values had r-squared of  0.49 and arithmetic mean of  3,862,889. View All Fundamentals
 
Selling And Marketing Expenses  
First Reported
2010-12-31
Previous Quarter
18 M
Current Value
18.9 M
Quarterly Volatility
7.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77 K, Interest Expense of 637.6 K or Selling General Administrative of 16.9 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 4.5. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
Check out the analysis of Oncolytics Biotech Correlation against competitors.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Latest Oncolytics Biotech's Selling And Marketing Expenses Growth Pattern

Below is the plot of the Selling And Marketing Expenses of Oncolytics Biotech over the last few years. It is Oncolytics Biotech's Selling And Marketing Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncolytics Biotech's overall financial position and show how it may be relating to other accounts over time.
Selling And Marketing Expenses10 Years Trend
Slightly volatile
   Selling And Marketing Expenses   
       Timeline  

Oncolytics Selling And Marketing Expenses Regression Statistics

Arithmetic Mean3,862,889
Geometric Mean929,278
Coefficient Of Variation183.84
Mean Deviation5,466,611
Median445,691
Standard Deviation7,101,477
Sample Variance50.4T
Range18.5M
R-Value0.70
Mean Square Error27.8T
R-Squared0.49
Significance0
Slope1,109,944
Total Sum of Squares706T

Oncolytics Selling And Marketing Expenses History

202418.9 M
202318 M
202215.7 M
2021452.5 K

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's Selling And Marketing Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling And Marketing Expenses18 M18.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.